News

Result of Special Meeting and Directors' Shareholdings
28 July 2014

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM JAPAN, CANADA OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

Further to the announcement dated 16 July 2014, TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce that at the Special Meeting held earlier today, each of the resolutions as set out in the notice of Special Meeting was duly passed. Accordingly, the Fundraise (as defined in the circular dated 16 July 2014) is now unconditional save for Admission.

Accordingly, the Company has approved, subject only to Admission, the issue of 50,000,000 new common shares in the capital of the Company of $0.001 each (the "New Common Shares") at 7 pence per share to the investors participating in the Fundraise.

Application has been made to the London Stock Exchange for the New Common Shares to be admitted to trading on AIM ("Admission"). It is now expected that Admission and the commencement of dealings will take place at 8 a.m. on 31 July 2014.

Following Admission, the Company will have 256,168,068 common shares of $0.001 each ("Common Shares") in issue, of which 1,084,413 will continue to be held in Treasury. Therefore, the total number of voting rights in the Company will be 255,083,655 ("Total Voting Rights"). The number of restricted Common Shares trading under TIDM 'TYR' following Admission will be 161,266,592 and the number of unrestricted Common Shares trading under TIDM 'TYRU' following Admission will be 94,901,476.

Furthermore, following Admission, there are changes to the following directors' holdings of Common Shares:

Alan Reade, who subscribed for 214,298 New Common Shares pursuant to the Subscription, is now interested in 12,700,656 Common Shares in the Company; representing an interest of 4.98% of the total voting rights of the Company.

Bruno Jactel, who subscribed for 142,857 New Common Shares pursuant to the Subscription, is now interested in 2,002,424 Common Shares in the Company; representing an interest of 0.79% of the total voting rights of the Company.

Barry Riley, who subscribed for 142,857 New Common Shares pursuant to the Subscription, is now interested in 3,198,413 Common Shares in the Company; representing an interest of 1.25% of the total voting rights of the Company.

James Hills, who subscribed for 142,857 New Common Shares pursuant to the Subscription, is now interested in 1,190,757 Common Shares in the Company representing an interest of 0.47% of the total voting rights of the Company.

 

For further information please contact:

TyraTech Inc.
Alan Reade, Non-Executive Chairman
Bruno Jactel, Chief Executive Officer

Tel: +44 7841978709
Tel: +1 919 415 4340
SPARK Advisory Partners Limited, Nominated Adviser
Matt Davis / Mark Brady

Tel: +44203 368 3551
Allenby Capital Limited , Joint Broker
Chris Crawford

Tel: +44 20 3328 5656
Whitman Howard Limited, Joint Broker
Ranald Mc-Gregor Smith / Niall Devins

Tel: +44 20 7087 4550
Walbrook, Financial PR and IR
Bob Huxford /Guy McDougall

Tel: +44 20 7933 8792

 

<< Back to News releases

Disclaimer for U.S. Site Visitors

This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.